Incyte Corporation

Yong Li

Wenqing Yao

Xiaozhao Wang

Liangxing Wu

Wenyu Zhu

Chao Qi

Peter Niels Carlsen

Pei Gan

Chunhong He

Juan C Almagro

Taisheng Huang

Le Zhao

Yingnan Chen

Shaun M Stewart

Gia Hoang

Rebecca A Buonpane

Horacio G Nastri

Jing Zhou

Chunyin Marshall Law

Hui Wang

Jeffrey Yang

Disclosed are compounds of Formula I, shown below, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Tricyclic compounds as inhibitors of KRAS

Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.

CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Fused pyrazine derivatives as A2A / A2B inhibitors

Growing community of inventors

Newark, DE, United States of America

Yong Li